If you download the right apps, your digital device can also be a health advantage.
Here are seven free health apps from iTunes, for iPhone and iPad — many of these are also available for Android, Blackberry and other platforms…
AirStrip – Patient Monitoring AirStrip is intended for use by clinicians who care for patients. In order to use AirStrip, your healthcare facility must have purchased and installed AirStrip. There is an off-line demo built into this application which will allow you to learn more about the features AirStrip has to offer.
BMI Tool Quickly calculate a patient’s body mass index (BMI), estimate risk of developing weight-related diseases, and determine appropriate treatment plans with the BMI Tool application. Access in-depth weight measurement calculators and tools with a variety of features.
Lifesaver Int Lifesaver shows you the defibrillators at doctors, trainstations, firedepos, airports, schools, hospitals, private companies, shopingcenters and many more… Support the Herzsicher project, in submit new worldwide position.
MedWatcher for drugs, vaccines and medical devices MedWatcher was created in collaboration with the US Food and Drug Administration (FDA) Center for Devices and Radiologic Health (CDRH). Use MedWatcher to get news and official safety alerts for medical devices, as well as drugs and vaccines. MedWatcher is the only app that allows you to report bad side effects or adverse events directly to the FDA to make medical products safer for everyone. MedWatcher is the only app that allows you to report bad side effects or adverse events directly to the FDA to make medical products safer for everyone.
SymTrend Select an electronic diary for depression, cancer, women’s health, chronic pain, ADHD, or the autism spectrum to help you understand symptom patterns, learn what triggers problems, see how well treatments are working, and get guidance to manage your own care.
The Oncologist The official journal of the Society for Translational Oncology (STO), is dedicated to helping oncology professionals provide optimal and innovative care for cancer patients by staying on the cutting edge of new medical treatments and technologies.
WebMD – Trusted Health and Wellness Information The NEW WebMD app incorporates personalized, engaging multimedia lifestyle content. WebMD for iPhone offers on-demand, healthy-living information, in addition to physician-reviewed health content and interactive tools. The innovative design marries content and utility informed by more than five years of user insights and feedback.
Testicular cancer may be elevated among DES-exposed men
2001 Study Abstract
An association between prenatal Diethylstilbestrol (DES) exposure and cancer in men, especially testicular cancer, has been suspected, but findings from case-control studies have been inconsistent. This study was conducted to investigate the association between prenatal DES exposure and cancer risk in men via prospective follow-up.
A total of 3613 men whose prenatal DES exposure status was known were followed from 1978 through 1994. The overall and site-specific cancer incidence rates among the DES-exposed men were compared with those of the unexposed men in the study and with population-based rates. The relative rate (RR) was used to assess the strength of the association between prenatal DES exposure and cancer development. All statistical tests were two-sided.
Overall cancer rates among DES-exposed men were similar to those among unexposed men (RR = 1.07; 95% confidence interval [CI] = 0.58 to 1.96) and to national rates (RR = 0.99; 95% CI = 0.65 to 1.44). Testicular cancer may be elevated among DES-exposed men, since the RRs for testicular cancer were 3.05 (95% CI = 0.65 to 22.0) times those of unexposed men in the study and 2.04 (95% CI = 0.82 to 4.20) times those of males in the population-based rates. The higher rate of testicular cancer in the DES-exposed men is, however, also compatible with a chance observation.
To date, men exposed to DES in utero do not appear to have an increased risk of most cancers. It remains uncertain, however, whether prenatal DES exposure is associated with testicular cancer.
Cancer risk in men exposed in utero to diethylstilbestrol,NCBI, PMID: 11287449, 2001 Apr 4;93(7):545-51. Full text: Oxford Journals Medicine & Health International Journal of Epidemiology link.
Les médecins signataires de ce texte se déclarent solidaires des demandes d’interdiction des épandages aériens et des mesures de réductions des risques pour les populations vivant à proximité des cultures à forte utilisation de pesticides. Ils demandent que la région Limousin “s’engage résolument vers l’objectif d’une réduction de 50% des pesticides d’ici 2020”.
DES-exposed women have a higher risk of infertility
2001 Study Abstract
Although it is well established that women exposed to diethylstilbestrol in utero have an increased risk of spontaneous abortion, ectopic pregnancy, and preterm delivery, it is not known whether they also have an increased risk of infertility. The authors assessed this question in data from a collaborative follow-up study of the offspring of women who took diethylstilbestrol during pregnancy. In 1994, 1,753 diethylstilbestrol-exposed and 1,050 unexposed women from an ongoing cohort study (National Cooperative Diethylstilbestrol Adenosis Study and Dieckmann cohorts) provided data on difficulties in conceiving and reasons for the difficulty. Age-adjusted relative risks were computed for the association of diethylstilbestrol exposure with specific types of infertility. A greater proportion of exposed than unexposed women were nulligravid (relative risk (RR) = 1.3, 95% confidence interval (CI): 1.1, 1.5), and a greater proportion had tried to become pregnant for at least 12 months without success (RR = 1.8, 95% CI: 1.6, 2.1). Diethylstilbestrol exposure was significantly associated with infertility due to uterine and tubal problems, with relative risks of 7.7 (95% CI: 2.3, 25) and 2.4 (95% CI: 1.2, 4.6), respectively. The present findings indicate that diethylstilbestrol-exposed women have a higher risk of infertility than do unexposed women and that the increased risk of infertility is primarily due to uterine or tubal problems.
Sadly for many DES daughters having their own children is not possible! Many of us who have experienced miscarriages, want to have kids but are struggling or unable to…
Infertility among women exposed prenatally to diethylstilbestrol,NCBI, PMID: 11495854, 2001 Aug 15;154(4):316-21. Full text: Oxford Journals Medicine & Health International Journal of Epidemiology link.
2013 Report of the Interagency Breast Cancer and Environmental Research Coordinating Committee
The February 2013 Congressional Mandated Committee report from the National Institutes of Health recommended a national strategy that shifts the focus of breast cancer research from diagnosis and treatment to the causes and prevention. An overview:
Breast Cancer Burden
Major Advances in Breast Cancer Prevention, Diagnosis, and Treatment
State of the Science: Part 1 – Principles, Approach, and Mechanisms
State of the Science: Part 2 – Evidence From Animal and Human Studies and CrossCutting Themes
Research Translation, Dissemination, and Communication of Research Related to Breast Cancer and the Environment: From Science to Society and Back Again
DES is a worldwide drug tragedy! If you’ve been exposed to diethylstilbestrol, you’re not alone. Contact your local DES Action Group for professional advice and support. In the United States alone it is estimated that 5 to 10 million people have been exposed to this drug. Other countries affected include the UK, France, the Netherlands, Ireland, Australia, Canada, and many more…
DES seems to have health effects across the lifespan, especially in the reproductive tract
DES Follow-up Study Summary
A recent analysis of data from questionnaires returned by the participants in the DES Follow-up Study suggests that exposed daughters tend to have a slightly earlier age at natural menopause than unexposed daughters (Hatch EE et al, Age at Natural Menopause in Women Exposed to Diethylstilbestrol in Utero, American Journal of Epidemiology, October 1, 2006). The researchers analyzed data on over 4210 exposed daughters and 1829 unexposed daughters, and accounted for other factors that could be related to the age at natural menopause, such as cigarette smoking, hormone use, pregnancy history, and the age of the mother’s menopause. The average age at menopause was 52.2 years in unexposed women and 51.5 years in DES-exposed women, equivalent to about a nine month earlier menopause. Women who had been exposed to higher cumulative doses of DES tended to have menopause even earlier than those who had lower doses. Although this relatively small difference in age at menopause should not be related to any major health problems among the DES daughters, it does highlight the fact that DES seems to have health effects across the lifespan, especially in the reproductive tract. In general, menopause is thought to occur when the number of ovarian follicles left in the ovaries reaches a ‘critical’ level, therefore it is possible that DES daughters may have been born with a smaller reserve of follicles than unexposed women.
2006 Study Abstract
Age at natural menopause is related to several health outcomes, including cardiovascular disease and overall mortality. Age at menopause may be influenced by the number of follicles formed during gestation, suggesting that prenatal factors could influence menopausal age. Diethylstilbestrol (DES), a nonsteroidal estrogen widely prescribed during the 1950s and 1960s, is related to reproductive tract abnormalities, infertility, and vaginal cancer in prenatally exposed daughters but has not been studied in relation to age at menopause. The authors used survival analyses to estimate the risk of natural menopause in 4,210 DES-exposed versus 1,829 unexposed US women based on responses to questionnaires mailed in 1994, 1997, and 2001. DES-exposed women were 50% more likely to experience natural menopause at any given age (hazard ratio = 1.49, 95% confidence interval: 1.28, 1.74). Among women for whom dose information was complete, there were dose-response effects, with a greater than twofold risk for those exposed to >10,000 mg. The causal mechanism for earlier menopause may be related to a smaller follicle pool, more rapid follicle depletion, or changes in hormone synthesis and metabolism in DES-exposed daughters. Age at menopause has been related, albeit inconsistently, to several exposures, but, to the authors’ knowledge, this is the first study to suggest that a prenatal exposure may influence reproductive lifespan.
Age at natural menopause in women exposed to diethylstilbestrol in utero,NCBI, PMID: 16887893, 2006 Oct 1;164(7):682-8. Epub 2006 Aug 3. Full text Oxford Journals Medicine & Health International Journal of Epidemiology link.
Results of thousands of clinical trials remain unreported and the information that they generate remains invisible to both the scientific community and the public. Pharmaceutical companies and medical researchers are putting patients’ lives in danger by failing to publish unfavourable results from clinical trials, MPs have warned.
The lack of transparency means many trials are not registered before they are done, while results are held as private documents that cannot be scrutinised by patients or independent experts. Many drugs – such as Dépakine, Epilim, Valproate – would not have done the damage it has if trials results had been registered and published.
Evidence de perturbations hormonales chez des ouvriers exposés, dans le cadre professionnel, aux phtalates
Une étude parue en mars 2012 sur le site de la revue britannique Human Reproduction met en évidence que l’exposition des testicules de l’homme adulte aux phtalates – un plastifiant – entraîne une inhibition de la production de l’hormone masculine, la testostérone. Jusqu’ici, un tel effet n’avait été constaté que sur les testicules de fœtus humain ou chez le rongeur.